<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047666</url>
  </required_header>
  <id_info>
    <org_study_id>CLEAR1.0</org_study_id>
    <nct_id>NCT05047666</nct_id>
  </id_info>
  <brief_title>COVID-Like Illness Respiratory Pathogens. A Prospective Cohort on the COVID-19 Post-acute Condition</brief_title>
  <acronym>CLEAR</acronym>
  <official_title>CLEAR: COVID-Like Illness Respiratory Pathogens - Diagnostics Response in Ghana. A Prospective Cohort on the COVID-19 Post-acute Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bernhard Nocht Institute for Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kumasi Centre for Collaborative Research (KCCR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bernhard Nocht Institute for Tropical Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identifying multiorgan sequalae and complications through high quality, prospective matched&#xD;
      controlled studies throughout the course of COVID-19 is important for the acute and long-term&#xD;
      management of patients and for health systems' planning. Further, it is key to understand the&#xD;
      link between acute illness and long term consequences particularly in those already living&#xD;
      with other comorbidities such as cardiovascular diseases or cancer.&#xD;
&#xD;
      Since the clinical presentation of COVID-19 can resemble a variety of common respiratory&#xD;
      infections, describing the distribution of pathogens and the severity of clinical&#xD;
      presentation associated with COVID-like illnesses (CLI) infections is important to generate a&#xD;
      baseline clinical description by comparing potential long-term effects of PCR-confirmed&#xD;
      COVID-19 to those following other respiratory infections.&#xD;
&#xD;
      To gain a better understanding of the clinical burden on COVID-19 survivors we will undertake&#xD;
      a comparative evaluation within a cohort of PCR-confirmed individuals with COVID-19 vs. those&#xD;
      PCR-confirmed symptomatic individuals with other respiratory pathogens plus healthy&#xD;
      individuals from the community.&#xD;
&#xD;
      The results will inform strategies to prevent long term consequences; inform clinical&#xD;
      management, interventional research, direct rehabilitation, and inform public health&#xD;
      management to reduce overall morbidity and improve outcomes of COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational prospective matched cohort study to evaluate the post-acute&#xD;
      consequences of the SARS-CoV-2 symptomatic infection (case-positives) while having as&#xD;
      comparison groups (1) symptomatic controls (case-negatives) and (2) healthy controls, that&#xD;
      are healthy individuals recruited from the same community of the cases, but not arise from&#xD;
      the same household. After pre-screening of COVID-19 symptoms at the hospital and other&#xD;
      satellite health centers, consenting/assenting patients of 16 years of age and above with all&#xD;
      range of PCR-confirmed Covid-19 disease severity -from mild to severely ill hospitalized&#xD;
      patients- will be recruited and matched to other Non-SARS-CoV-2 PCR-determined patients and&#xD;
      to healthy community controls. Then, they will be followed up for 12 months (13 months after&#xD;
      screening) to determine the occurrence of admissions, any outpatient encounter, symptoms (new&#xD;
      or persistent) and concomitant use of medication after 28 days of diagnosis.&#xD;
&#xD;
      At recruitment, respiratory samples are collected for respiratory infections diagnosis. Also,&#xD;
      blood samples are collected to generate baseline data on potential biomarkers associated to&#xD;
      occurrence of investigated outcomes. This will include biochemistry (including inflammatory&#xD;
      markers) and hematology as well as SARS-CoV-2 serology (IgG) which will also be taken at the&#xD;
      end of follow up to rule out infection during the course of the follow up. Though, the&#xD;
      serology testing won't be done along each recruitment but in batches during the study period.&#xD;
      Clinical (symptoms and diagnosis), socioeconomic, demographic, household conditions, health&#xD;
      seeking behavior and medical history information will be gathered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Admissions and Outpatient encounter</measure>
    <time_frame>13 months</time_frame>
    <description>Cumulated number of admissions and outpatient encounters within 13 months post PCR diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistent or new symptoms</measure>
    <time_frame>13 months</time_frame>
    <description>Cumulated number of persistent/new symptoms within 13 months post PCR diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication and therapy</measure>
    <time_frame>13 months</time_frame>
    <description>Cumulated therapy and use within 13 months post PCR diagnosis defined as:&#xD;
Average weekly intake of particular medication(s)&#xD;
Newly use of a particular medication(s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients' symptoms outcome</measure>
    <time_frame>13 months</time_frame>
    <description>Occurrence of sequalae, post-acute symptoms and long-term patients' outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathogen detection</measure>
    <time_frame>13 months</time_frame>
    <description>Pathogens detected by PCR respiratory panel</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Endpoint 1</measure>
    <time_frame>13 months</time_frame>
    <description>Viral variants detection via sequencing in the subgroup of symptomatic PCR-positive SARS-CoV-2 patients using the test-negative design.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Endpoint 2</measure>
    <time_frame>13 months</time_frame>
    <description>Vaccine effectiveness in the subgroup of symptomatic PCR-positive SARS-CoV-2 patients using the test-negative design.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1232</enrollment>
  <condition>Respiratory Infection</condition>
  <condition>COVID-19 Respiratory Infection</condition>
  <condition>Sequelae of; Infection</condition>
  <arm_group>
    <arm_group_label>Cases Group</arm_group_label>
    <description>Also called in our study 'Case-Positives'. These are those with respiratory symptoms suspected of COVID-19 that actually test positive (PCR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symptomatic Control Group</arm_group_label>
    <description>Also called in our study 'Case-Negatives'. These are those with respiratory symptoms suspected of COVID-19 that actually test negative for SARS-CoV-2 but positive for any other pathogen included in our respiratory PCR-based panel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Group</arm_group_label>
    <description>At the community.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Respiratory samples (PCR), Blood Samples (Hematology, Biochemistry, Serology)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study takes place in Assin Foso, Assin North District, Ghana. This is a semi rural&#xD;
        area. Participants are recruited from the Saint Francis Xavier Hospital, the reference&#xD;
        center of the region, when the seek for health services due to respiratory symptoms.&#xD;
        Healthy controls are recruited from the communities from where cases arise.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. For symptomatic patients attending to the SFXH or other satellite health centers&#xD;
&#xD;
               -  Inclusion Criteria&#xD;
&#xD;
                    1. Patients &gt; or =16 years of age&#xD;
&#xD;
                    2. Presenting respiratory symptoms&#xD;
&#xD;
                    3. Positive respiratory sample for SARS-CoV-2 or other respiratory infections&#xD;
                       included in the panel&#xD;
&#xD;
                    4. Possibility to be contacted during follow-up&#xD;
&#xD;
                    5. Consented participation&#xD;
&#xD;
                    6. Patients which households are located within the study catchment area&#xD;
&#xD;
               -  Exclusion Criteria&#xD;
&#xD;
                    1. Symptomatic patients who test negative for all pathogens of the PCR-based&#xD;
                       respiratory panel.&#xD;
&#xD;
                    2. Symptomatic patients who test negative for the SARS-CoV-2 RDT and do not&#xD;
                       meet the matching criteria (age and residency (community)) as symptomatic&#xD;
                       controls to any of the recruited cases (to be considered as controls for the&#xD;
                       Antimicrobial Use Workpackage)&#xD;
&#xD;
          2. Antimicrobial Use Work package (A subset of hospitalized, symptomatic patients are to&#xD;
             be recruited as control group for the Antimicrobial Use Workpackage, if they meet the&#xD;
             inclusion criteria)&#xD;
&#xD;
               -  Inclusion Criteria&#xD;
&#xD;
                    1. Patients &gt; or =16 years of age&#xD;
&#xD;
                    2. Presenting respiratory symptoms&#xD;
&#xD;
                    3. Negative respiratory sample for SARS-CoV-2 (RDT)&#xD;
&#xD;
                    4. Do not meet the matching criteria (age and residency (community)) as&#xD;
                       symptomatic controls to any of the recruited cases&#xD;
&#xD;
                    5. Admitted to SFXH&#xD;
&#xD;
                    6. Consented participation&#xD;
&#xD;
          3. For healthy controls from the community&#xD;
&#xD;
               -  Inclusion Criteria&#xD;
&#xD;
                    1. Patients &gt; or =16 years of age&#xD;
&#xD;
                    2. Meet the age and residency (community) criteria to be matched to the cases&#xD;
&#xD;
                    3. Possibility to be contacted during follow-up&#xD;
&#xD;
                    4. Consented participation&#xD;
&#xD;
               -  Exclusion Criteria&#xD;
&#xD;
                    1. Presenting COVID-19 like symptoms&#xD;
&#xD;
                    2. Positive for SARS-CoV-2 RDT Eligible participants in the community&#xD;
                       presenting with an acute illness can be considered for inclusion as a case&#xD;
                       and recommended for referral to SFXH/ satellite health centre.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Strauss, Dr.MD. MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bernhard Nocht Institute for Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JÃ¼rgen May, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bernhard Nocht Institute for Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oumou Maiga-Ascofare, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kumasi Center for Collaborative Research in Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Amuasi, MBChB, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kumasi Center for Collaborative Research in Tropical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Strauss, Dr. MD. MPH</last_name>
    <phone>+49 40 42818 243</phone>
    <email>ricardo.strauss@bnitm.de</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

